Haemonetics to Acquire Vivasure to Strengthen Large-Bore Closure Portfolio

Haemonetics has agreed to acquire Ireland-based Vivasure Medical in a deal aimed at expanding its presence in rapidly growing structural heart and endovascular markets. Under the agreement, Haemonetics will pay €100 million upfront, with the net value reduced to about €52 million when prior investments and loans are factored in. Vivasure could also receive up to €85 million in additional payments if it achieves specified sales and growth targets.

Vivasure develops PerQSeal Elite, a biosorbable patch system designed to close large-bore arterial or venous access sites from within the vessel. The device received CE mark approval in Europe last year for venous closure, following earlier authorization for arterial use. Vivasure also submitted a premarket approval application to the U.S. FDA after clinical data showed no complications at 30 days.

The acquisition will allow Haemonetics to extend its vascular closure offerings into complex procedures such as transcatheter valve replacement, reinforcing its strategy of investing in high-growth cardiac technologies.

12-01-2026